Terms Of Use - Reconcile® (fluoxetine hydrochloride)

Product Details
BOND® Training Information
Prescribing Information
FAQ
Behavior Bits
Get In Touch

Product Details
BOND® Training Information
Prescribing Information
FAQ
Behavior Bits
Get In Touch

Get in Touch

Fill out the form below and a PRN Pharmacal sales representative will get in touch with you.

IMPORTANT SAFETY INFORMATION: The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. For product label, including complete safety information, see package insert.

NADA#141-272

The information, tools and material presented on this site are provided for informational and educational purposes only. Please consult your veterinarian for an official diagnosis of canine separation anxiety and to learn more about Reconcile. Click here to read the complete terms and conditions regarding use of this website.

Terms Of Use

PRN® and Reconcile® are registered trademarks of Pegasus Laboratories, Inc.

Return to top